Slide 1: Proven Ability In Life Sciences
Proven Ability In Life Sciences November 18, 2025 To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra-Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip code: 512529 Scrip code: SEQUENT Dear Sir/ Madam, Sub
Slide 2: Press Release: NCLT Approval for Transformational Merger
Press Release SeQuent Scientific and Viyash Lifesciences Receive NCLT Approval for Transformational Merger • Combined Strengths Poised to Create a Global Animal Health Powerhouse • Q2 FY25–26: Combined Sales Up 16%, EBITDA Surges 76%, underscoring the operational and strategic synergies emerging from
Slide 3: About SeQuent Scientific and Viyash Lifesciences
About SeQuent Scientific SeQuent Scientific Limited (BSE: 512529, NSE: SEQUENT), headquartered in India, operates in the Animal Health market with a global footprint. SeQuent has seven manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from international regulatory bodies
Slide 4: Investor Presentation Q2 FY26
INVESTOR PRESENTATION Q2 FY26 SEQUENT SCIENTIFIC LIMITED 18th Nov 2025
Slide 5: Steadfast commitment to improvement in business fundamentals
Steadfast commitment to improvement in business fundamentals “The results of Q2 FY 25-26 and the first half FY 25-26 reinforce the transformational journey undertaken by the company. Revenue, margins and profits have continued to show healthy growth on the back of new product introductions, superior
Slide 6: Q2FY26 Combined Performance
Q2FY26 Combined Performance
Slide 7: Q2 FY26 Performance Highlights
Q2 FY26 Performance Highlights Net Debt to LTM Revenues EBITDA1 EBITDA margin EBITDA1 ₹8,521 ₹1,890 22.2% 0.7x Million Million +16 % +76% +750 bps 1.4x in Q2 YoY YoY YoY FY25 4 Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs. 2. Financials presented are Pro forma financials (unau
Slide 8: Broad based revenue growth across all businesses
Broad based revenue growth across all businesses All values in ₹ Mn Revenue Distribution Q2 FY26 Q2 FY25 YoY Gr% Q1 FY26 QnQ Gr% H1 FY26 H1 FY25 YoY Gr% Formulations 3,364 2,836 18.6% 3,383 (0.5%) 6,747 5,837 15.6% Europe 1,533 1,335 14.8% 1,640 (6.5%) 3,172 2,910 9.0% Emerging Markets 1,469 1,160 2
Slide 9: H1 FY26 Performance Highlights
All values in ₹ Mn H1 FY26 Performance Highlights Net Debt to LTM Revenues EBITDA1 EBITDA margin EBITDA1 ₹16,462 ₹3,180 19.3% 0.7x Million Million +12.6 % +48% +460 bps 1.4x in H1 YoY YoY YoY FY25 6 Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs 2. Financials presented are Pro f
Slide 10: Combined P&L Snapshot
Combined P&L Snapshot 7 Note: Financials presented are Pro forma financials (unaudited) for guidance on combined performance without incorporating any merger-related adjustments 1. Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses (Viyash)
Slide 11: Combined Balance Sheet Snapshot
Combined Balance Sheet Snapshot All values in ₹ Mn Combined Particulars As of 30 Sep 2025 Shareholders' Funds 26,146 Minority Interest 1,674 Net Debt 4,095 Key Ratios Combined Other Non current Liabilities 2,362 Net Debt to Equity 0.2x Total Liabilities 34,276 Net Debt to EBITDA 0.7x Tangible Assets
Slide 12: Merger Update
Merger Update nS
Slide 13: Merger – Process Update
Merger – Process Update Merger process status update • NCLT approval order reserved on Oct 31, 2025; order pronounced on Nov 18, 2025 • Focus on synergy realization for next 12 months 10
Slide 14: Synergy Update
Synergy Update 11 In advanced stages
Slide 15: New production block commissioned in record time
New production block commissioned in record time New production block created in short time to improve capacity, productivity and cost of Sequent products One large volume Sequent API validated & filing under progress 12
Slide 16: Business Update - Sequent
Business Update - Sequent nS
Slide 17: SeQuent: Q2FY26 Business Performance
SeQuent: Q2FY26 Business Performance All values in ₹ Mn Europe: Significant growth in Spain with good exports performance 1,000+ FDFs Emerging Markets: Formulations Launched Tulaject in Brazil & received MA for Mexico market 90+ R&D infrastructure expanded Countries India: Business beginning to
Slide 18: Business Update - Viyash
Business Update - Viyash nS
Slide 19: Viyash: Q2 FY26 Key growth drivers
Viyash: Q2 FY26 Key growth drivers New products launches Focus on CDMO business Improved product mix Network optimisation for better efficiencies Backward and Forward integration 16
Slide 20: Key updates from Q2 FY26
Key updates from Q2 FY26 Facility Inspections Regulatory Approvals Launches 4 Regulatory Audits 2APIs: (USDMF-1 ; 2 FDFs (US) 56 Customer audits EDQM-1 2 APIs 1 US FDA EIR Products Filed Validations Completed R&D Pipeline 9 Filings – SFDA(3), 3 APIs 16+ Products EDQM (1) TGA (1), EDMF (2), WHO (1),
Slide 21: For details, feel free to contact
For details, feel free to contact: Yoshita Vora Abhishek Singhal Company Secretary Investor Relations Consultant +91 22 4111 4777 abhishek@arunya.co.in investorrelations@sequent.in Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Sh
Slide 22: Thank You
Thank You